Physiomics Regulatory News (PYC)

Physiomics plc

("Physiomics" or "the Company")

Physiomics to present on Lilly Collaboration at the Annual Meeting for American Association for Cancer Research ("AACR")

Physiomics (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it will be participating in the AACR 102nd Annual Meeting 2011, taking place in the Orange County Convention Center, Orlando, Florida on 2-6 April 2011.

Dr Eric Fernandez, Project Leader at Physiomics, will present on a validation of our Virtual Tumour platform, which was completed in collaboration with Eli Lilly and Company ('Lilly') the global biopharmaceutical company.

In this validation study, Physiomics' Virtual Tumour model accurately predicted tumour growth in a pre-clinical model for two anti-cancer drug combinations, using experimental data collected from single drug exposures. This test was conducted in a single-blind manner, the experimental results of the combinations being revealed to Physiomics only after Physiomics had provided the Virtual Tumour simulation results to Lilly.

The Virtual Tumour platform is used to design optimal combination chemotherapy regimens. Thousands of simulations can be performed in silico if necessary to find the best treatment regime and save biopharmaceutical customers like Lilly time and money.

The abstract ("Predicting the effect of combination schedules on xenograft tumor using the Virtual Tumor", No 4918) will be published in the 2011 Proceedings of the AACR and will be presented in the "Integrative Genomic Biology" poster session, scheduled 08:00 AM - 12:00 PM, 6 April 2011.

More information about the conference may be found at:

http://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011.aspx

Dr Mark Chadwick, CEO of Physiomics, said

"We are particularly pleased to present these results at this year's AACR annual meeting. We believe this blind validation approach will attract further large pharma customers."

Enquiries:

Physiomics plc

Dr Mark Chadwick, CEO

+44 (0)1865 784 980

WH Ireland Limited

Katy Mitchell

+44 (0) 161 832 2174

Information on Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. As 80-90 per cent of all clinical drug candidates fail to reach the market, estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The models are used to optimise compound design, as well as to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com